Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12185-013-1441-6 | DOI Listing |
Breast Cancer Res
June 2024
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Cancers (Basel)
November 2022
MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited therapeutic options. Although immunotherapy has shown potential in TNBC patients, clinical studies have only demonstrated a modest response. Therefore, the exploration of immunotherapy in combination with chemotherapy is warranted.
View Article and Find Full Text PDFCell Rep Med
June 2022
Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden. Electronic address:
Understanding the complete immune cell composition of human neuroblastoma (NB) is crucial for the development of immunotherapeutics. Here, we perform single-cell RNA sequencing (scRNA-seq) on 19 human NB samples coupled with multiplex immunohistochemistry, survival analysis, and comparison with normal fetal adrenal gland data. We provide a comprehensive immune cell landscape and characterize cell-state changes from normal tissue to NB.
View Article and Find Full Text PDFFront Genet
June 2021
Department of Animal Science, Iowa State University, Ames, IA, United States.
Pigs are a valuable human biomedical model and an important protein source supporting global food security. The transcriptomes of peripheral blood immune cells in pigs were defined at the bulk cell-type and single cell levels. First, eight cell types were isolated in bulk from peripheral blood mononuclear cells (PBMCs) by cell sorting, representing Myeloid, NK cells and specific populations of T and B-cells.
View Article and Find Full Text PDFFront Immunol
September 2021
University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France.
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest cancers worldwide. Advanced HCC overall survival is meager and has not improved over the last decade despite approval of several tyrosine kinase inhibitors (TKi) for first and second-line treatments. The recent approval of immune checkpoint inhibitors (ICI) has revolutionized HCC palliative care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!